Cyclacel Pharmaceuticals, Inc.·4

Jul 3, 4:57 PM ET

McBarron Paul 4

4 · Cyclacel Pharmaceuticals, Inc. · Filed Jul 3, 2023

Insider Transaction Report

Form 4
Period: 2023-06-30
McBarron Paul
DirectorEVP, Finance, CFO, COO
Transactions
  • Award

    Stock Option (right to buy)

    2023-06-30+70,20070,200 total
    Exercise: $0.59From: 2024-06-30Exp: 2033-06-30Common Stock (70,200 underlying)
Footnotes (1)
  • [F1]The reporting person received an award of 70,200 options on June 30, 2023, which shall vest in full on June 30, 2026, provided, however, that if certain clinical milestones are achieved then such options shall vest in full earlier in connection with such achievement.

Documents

1 file
  • 4
    tm2320411-6_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT